Abstract:The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 9.2 million confirmed cases and 478,000 deaths (as of June 24th, 2020). The high intensive care unit (ICU) admission rate and mortality of COVID-19 is continuously posing a serious strain on the global health-care system. While most patients present with mild to moderate symptoms, some patients may develop life-threatening sepsis, respiratory failure, acute respiratory distress syndrome (ARDS) and multiple organ failure. However, current antiviral and supportive therapies are not sufficient to prevent or treat the above complications especially in severely ill COVID-19 patients [1]. Thus, it is urgent to find the underlying mechanism dominating such life-threatening complications. It is well recognized that lung damage and multi-organ failure in this subgroup of patients arise due to overwhelming systemic hyper-inflammation. Therefore, promising anti-inflammatory candidate agents targeting diverse mechanisms related to cytokine storm will be therapeutically relevant (Fig. 1 ). Open in a separate window Fig. 1 Potential therapies of COVID-19 by targeting inflammation and cytokine storm. SARS-CoV-2 enters and infects cells by binding to TMPRSS2 and ACE2, subsequently releases virus RNA, one of the PAMPs, and recruits dendritic cells, macrophages and neutrophils. The released type I interferon and pro-inflammatory cytokines and chemokines induce the innate immune response while adaptive immune response is ignited by activating T and B lymphocytes to defend against the virus. Meanwhile, intact viruses or the components can directly activate the NLRP3 inflammasome, leading to IL-1β secretion. In most infections, moderate immune response and antiviral response are capable to combat the infection. Nevertheless, in individuals with immunological dysfunction, persistent hyper-inflammation triggers a cytokine storm, leading to the lung injury and ARDS or eventually swept through the whole body, causing MODS. During the pathological progression, the inhibition of NRLP3, JAK1/2, IL-6, BRD4 and the infusion of IVIG may be beneficial in suppressing the overwhelming inflammation and arrest or reverse the COVID-19 disease. Abbreviations: ACE2, angiotensin converting enzyme 2; ARDS, acute respiratory distress syndrome; IVIG, intravenous immunoglobulin; MODS, multiple organ dysfunction syndrome; NLRP3, Nod-like receptor protein 3; PAMP, pathogen-associated molecular pattern; TMPRSS2, transmembrane serine protease 2.

Crosslinking the EcoRV restriction endonuclease across the DNA‐binding site reveals transient intermediates and conformational changes of the enzyme during DNA binding and catalytic turnover

Longitudinal Clinical and Radiographic Evaluation Reveals Interleukin-6 As an Indicator of Persistent Pulmonary Injury in COVID-19

Deep phenotyping of the lipidomic response in COVID-19 and non-COVID-19 sepsis

Lipid Mediators and Cytokines/Chemokines Display Differential Profiles in Severe versus Mild/Moderate COVID-19 Patients

Acetylcholine, Fatty Acids, and Lipid Mediators Are Linked to COVID-19 Severity

Hypersensitivity in the Lungs is Responsible for Acute Respiratory Failure in COVID‐19 Patients: Case Series of Patients Who Received High‐dose/short‐term Methylprednisolone

Polyunsaturated fatty acid-derived lipid mediator networks characterize COVID-19 severity and risk for critical illness

SARS-CoV-2 Infection Triggers Profibrotic Macrophage Responses and Lung Fibrosis

High plasma concentration of non-esterified polyunsaturated fatty acids is a specific feature of severe COVID-19 pneumonia

Multicentric investigations of the role in the disease severity of accelerated phospholipid changes in COVID-19 patient airway

Bronchoalveolar Lavage Single-Cell Transcriptomics Identifies Immune Cells Driving COVID-19 Severity in Patients

Characterization of the Inflammatory Response to Severe COVID-19 Illness

Aveolar Macrophage Activation and Cytokine Storm in the Pathogenesis of Severe COVID-19

Mediators of monocyte chemotaxis and matrix remodeling are associated with mortality and pulmonary fibroproliferation in patients with severe COVID-19

Targeting Inflammation and Cytokine Storm in COVID-19

Determination of triglycidyl isocyanurate from air samples by ultra-performance liquid chromatography coupled with coordination ion spray mass spectrometry.

CXCL10 could drive longer duration of mechanical ventilation during COVID-19 ARDS

Bioactive Lipids in COVID-19-Further Evidence

COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis

Chronic Obstructive Pulmonary Disease Patients Have Increased Levels of Plasma Inflammatory Mediators Reported Upregulated in Severe COVID-19

Oxylipin concentration shift in exhaled breath condensate (EBC) of SARS-CoV-2 infected patients